Cognetivity Neurosciences (CSE: CGN) continues to expand its footprint within the Middle East. This morning, the company indicated that it has entered into a collaboration agreement with PRIME Health, whom is a leading healthcare services provider within the UAE.
The collaboration agreement will see a pilot project undertaken for the use of Cognetivity’s integrated cognitive assessment tool, known as the CognICA platform. The goal of the pilot will effectively be the integration of the tablet-based application into the suite of corporate client services currently offered by Prime across the UAE.
Initial trials of the program will be conducted on a target number of patients at each clinic operated by Prime, which will be used to collect data on cognitive testing for its corporate participants, the goal of which is several potential benefits to patient outcomes, such as improved mental health screening as well as an improved quality of referrals.
“We are grateful for the Collaboration and the opportunity to help conduct the program. I am encouraged that it will lead to further opportunities to serve the cognitive wellness community and provide a higher level of care to corporate clients and other patients throughout the Prime network. The ability to provide accurate and quick cognitive assessments around the world is what fuels the Cognetivity team, and this Collaboration is a great way to continue doing that,” said Cognetivity CEO Sina Habibi on the pilot project.
Prime currently has facilities located across the UAE, which include a brand new 100-bed hospital as well as specialty clinics found within Dubai, Sharjah and Ajman. The company currently services an estimated 5,000 patients a day across all locations.
The pilot project is currently expected to lead to additional collaborations and opportunities in the future.
The development follows the company entering into a commercial agreement with the Dubai Health Authority for the deployment of the firms integrated cognitive assessment tool. That arrangement will see the firms tech deployed at some of the busiest dementia clinics within Dubai, while also exploring the possibility of screening the entire population for early signs of dementia.
Cognetivity Neurosciences last traded at $0.355 on the CSE.
FULL DISCLOSURE: Cognetivity Neurosciences Ltd is a client of Canacom Group, the parent company of The Deep Dive. The author has been compensated to cover Cognetivity Neurosciences Ltd on The Deep Dive, with The Deep Dive having full editorial control. We may buy or sell securities in the company at any time. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.
